comparison the therapeutic effect of pioglitazone and carnitine to pioglitazone and vitamin E in patients with non alcoholic fatty liver disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190701044062N8

Enrollment

Registered

2021-09-26

Start date

2019-10-23

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non alcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: pioglitazone 30mg daily and carnitine 1000mg daily for 6 months. Intervention 2: Control group: pioglitazone 30mg daily and vitamin E 800mg daily for 6 months.

Eligibility

Sex/Gender

All

Age

17 Years to 50 Years

Inclusion criteria

Inclusion criteria: Patients with non alcoholic fatty liver disease

Exclusion criteria

Exclusion criteria: Patients with liver disease such as viral hepatitis, autoimmune hepatitis, Wilson, hemochromatosis, liver cirrhosis, and PBC and PSC Patients who drink alcohol Patients with renal Failure (Creatinine > 1.5 mg/dl) Patients with known severe systemic disease and malignancy. Pregnancy or breastfeeding Patients with type 1 diabetes

Design outcomes

Primary

Measure	Time frame
Liver enzymes levels. Timepoint: At baseline, 3 and 6 months after the intervention. Method of measurement: Laboratory methods.;Ultrasound grade. Timepoint: At baseline and 6 months after intervention. Method of measurement: Perform liver ultrasound.	—

Secondary

Measure	Time frame
. Timepoint: . Method of measurement: .	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactManouchehr Khoshbaten

Tabriz University of Medical Sciences

mkhoshbaten@yahoo.com+98 41 3336 0840

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026